Cue Biopharma (NASDAQ:CUE) just reported results for the first quarter of 2024.
- Cue Biopharma reported earnings per share of -25 cents. This was above the analyst estimate for EPS of -28 cents.
- The company reported revenue of $1.72 million.
- This was 41.90% better than the analyst estimate for revenue of $1.21 million.